|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EA12
|
|
gptkbp:brand
|
Bosulif
|
|
gptkbp:CASNumber
|
380843-75-4
|
|
gptkbp:chemicalClass
|
quinoline
|
|
gptkbp:contraindication
|
hypersensitivity to bosutinib
|
|
gptkbp:developer
|
gptkb:Pfizer
|
|
gptkbp:drugInteraction
|
gptkb:proton_pump_inhibitors
CYP3A4 inhibitors
CYP3A4 inducers
|
|
gptkbp:eliminationHalfLife
|
22 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C26H29Cl2N5O3
|
|
gptkbp:hasSMILES
|
CC1=CC2=C(C=C1)N=C(C=C2Cl)NC(=O)C3=CC(=C(C=C3)Cl)NC4=NC=CC(=C4)C5CCN(CC5)C(=O)C
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bosutinib
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
BCR-ABL tyrosine kinase inhibition
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
94%
|
|
gptkbp:PubChem_CID
|
DB06616
4481391
5328940
CHEMBL1077510
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
elevated liver enzymes
thrombocytopenia
|
|
gptkbp:synonym
|
SKI-606
|
|
gptkbp:target
|
gptkb:BCR-ABL
SRC family kinases
|
|
gptkbp:UNII
|
G9B4J8MN7N
|
|
gptkbp:usedFor
|
gptkb:chronic_myelogenous_leukemia
|
|
gptkbp:bfsParent
|
gptkb:BCR-ABL
gptkb:chronic_myeloid_leukemia
|
|
gptkbp:bfsLayer
|
6
|